Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection
© 2022. The Author(s)..
We studied humoral and cellular immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 152 long-term care facility staff and 124 residents over a prospective 4-month period shortly after the first wave of infection in England. We show that residents of long-term care facilities developed high and stable levels of antibodies against spike protein and receptor-binding domain. Nucleocapsid-specific responses were also elevated but waned over time. Antibodies showed stable and equivalent levels of functional inhibition against spike-angiotensin-converting enzyme 2 binding in all age groups with comparable activity against viral variants of concern. SARS-CoV-2 seropositive donors showed high levels of antibodies to other beta-coronaviruses but serostatus did not impact humoral immunity to influenza or other respiratory syncytial viruses. SARS-CoV-2-specific cellular responses were similar across all ages but virus-specific populations showed elevated levels of activation in older donors. Thus, survivors of SARS-CoV-2 infection show a robust and stable immunity against the virus that does not negatively impact responses to other seasonal viruses.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
Nature aging - 2(2022), 6 vom: 28. Juni, Seite 536-547 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tut, Gokhan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies |
|---|
| Anmerkungen: |
Date Completed 01.05.2023 Date Revised 14.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s43587-022-00224-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356218643 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356218643 | ||
| 003 | DE-627 | ||
| 005 | 20240214232705.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s43587-022-00224-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM356218643 | ||
| 035 | |a (NLM)37118449 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tut, Gokhan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Robust SARS-CoV-2-specific and heterologous immune responses in vaccine-naïve residents of long-term care facilities who survive natural infection |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.05.2023 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a We studied humoral and cellular immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 152 long-term care facility staff and 124 residents over a prospective 4-month period shortly after the first wave of infection in England. We show that residents of long-term care facilities developed high and stable levels of antibodies against spike protein and receptor-binding domain. Nucleocapsid-specific responses were also elevated but waned over time. Antibodies showed stable and equivalent levels of functional inhibition against spike-angiotensin-converting enzyme 2 binding in all age groups with comparable activity against viral variants of concern. SARS-CoV-2 seropositive donors showed high levels of antibodies to other beta-coronaviruses but serostatus did not impact humoral immunity to influenza or other respiratory syncytial viruses. SARS-CoV-2-specific cellular responses were similar across all ages but virus-specific populations showed elevated levels of activation in older donors. Thus, survivors of SARS-CoV-2 infection show a robust and stable immunity against the virus that does not negatively impact responses to other seasonal viruses | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Influenza Vaccines |2 NLM | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 700 | 1 | |a Lancaster, Tara |e verfasserin |4 aut | |
| 700 | 1 | |a Butler, Megan S |e verfasserin |4 aut | |
| 700 | 1 | |a Sylla, Panagiota |e verfasserin |4 aut | |
| 700 | 1 | |a Spalkova, Eliska |e verfasserin |4 aut | |
| 700 | 1 | |a Bone, David |e verfasserin |4 aut | |
| 700 | 1 | |a Kaur, Nayandeep |e verfasserin |4 aut | |
| 700 | 1 | |a Bentley, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Amin, Umayr |e verfasserin |4 aut | |
| 700 | 1 | |a Jadir, Azar T |e verfasserin |4 aut | |
| 700 | 1 | |a Hulme, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Ayodel, Morenike |e verfasserin |4 aut | |
| 700 | 1 | |a Dowell, Alexander C |e verfasserin |4 aut | |
| 700 | 1 | |a Pearce, Hayden |e verfasserin |4 aut | |
| 700 | 1 | |a Zuo, Jianmin |e verfasserin |4 aut | |
| 700 | 1 | |a Margielewska-Davies, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Verma, Kriti |e verfasserin |4 aut | |
| 700 | 1 | |a Nicol, Samantha |e verfasserin |4 aut | |
| 700 | 1 | |a Begum, Jusnara |e verfasserin |4 aut | |
| 700 | 1 | |a Jinks, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Tut, Elif |e verfasserin |4 aut | |
| 700 | 1 | |a Bruton, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Krutikov, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Shrotri, Madhumita |e verfasserin |4 aut | |
| 700 | 1 | |a Giddings, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Azmi, Borscha |e verfasserin |4 aut | |
| 700 | 1 | |a Fuller, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a Irwin-Singer, Aidan |e verfasserin |4 aut | |
| 700 | 1 | |a Hayward, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Copas, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Shallcross, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Moss, Paul |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature aging |d 2021 |g 2(2022), 6 vom: 28. Juni, Seite 536-547 |w (DE-627)NLM322756456 |x 2662-8465 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2022 |g number:6 |g day:28 |g month:06 |g pages:536-547 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s43587-022-00224-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2022 |e 6 |b 28 |c 06 |h 536-547 | ||